Lise L. Kjems, M.D., Ph.D. has served as our Vice President, Clinical Development since February 2018. She has more than 17 years of global industry experience in both pharmaceutical and biotechnology companies based in the United States and Europe. Prior to joining Aldeyra, Dr. Kjems served as an Executive Medical Director at Intarcia Therapeutics, a privately held biotechnology company, overseeing the global phase 3 development and clinical pharmacology program for a combination drug product intended for the treatment of type 2 diabetes. Prior to that, from December 2005 to April 2014, she served in various roles of increasing responsibility at Novartis, leading programs and teams in translational medicine, and as Global Medical Program Director for late-stage development program. Her focus was on research and development of multiple new molecular entities including first-in-class across several therapeutic areas including cardiovascular, diabetes, and metabolism. During her tenure at Novartis, she also held a senior position in then newly formed Molecular Diagnostic Business Unit as an Executive Director, Senior Global Diagnostic Program Director, developing the strategy and leading a large matrix team for a companion diagnostic in support of a CNS development program. She also served as global medical program director for a number of diagnostic programs across multiple indications. From 2004 to 2005, she served as Executive Director, Global Project Team Leader at Ionis Pharmaceuticals, formerly Isis Pharmaceuticals, overseeing the development of their two lead cardiovascular and metabolism programs. Dr. Kjems also held senior clinical leadership positions in clinical drug evaluation at Janssen Pharmaceutical from 2002 to 2004 and as a Senior Clinical Pharmacologist, serving as the clinical lead to the cardiometabolic research team at Eli Lilly 2001 to 2002. Dr. Kjems received her medical degree and PhD from the University of Copenhagen and completed a post doctoral fellowship at the University of Edinburgh.
Back to Leadership Team & Board of Directors